open access

Vol 4, No 2 (1999)
Original papers
Published online: 1999-01-01
Submitted: 1999-08-28
Get Citation

Dose escalation using 3-dimensional conformal radiotherapy in management of non-small cell lung cancer; preliminary results on 22 patients

L. Kępka, P. Kukołowicz, J. Fijuth
DOI: 10.1016/S1507-1367(99)70312-3
·
Rep Pract Oncol Radiother 1999;4(2):29-37.

open access

Vol 4, No 2 (1999)
Original papers
Published online: 1999-01-01
Submitted: 1999-08-28

Abstract

Purpose

To determine the feasibility of radiation dose escalation > 70 Gy to Gross Tumour Volume (GTV) using 3-Dimensional Conformal Radiotherapy (3-DCRT).

Methods and Materials

From December 1997 to November 1998, 22 patients with non-small cell lung cancer (NSCLC) were included. Tumour stage was I in 3 cases, II in 6 cases, III in 10 cases, and there were 3 locoregional recurrences after surgery. A 3-D treatment planning system with BEV was used for all patients. Patients underwent limited elective nodal irradiation of 56 Gy. The GTV with 1 cm margin received a dose of at least 70 Gy. Acute and late toxicity were estimated according to the RTOG/EORTC score.

Results

The mean follow-up was 217 (80–360) days. Seventeen patients received 74 Gy, two had 72 Gy, and one had 70 Gy. In one patient with the largest irradiation volume a toxic death due to radiation pneumonitis occured. Except this fatality acute toxicity was acceptable. Seventeen patients were evaluable for response. There were 3 (18%) complete responses, all in patients staged I and II, seven (41%) partial responses, 5 (29%) non-responses and two (12%) local progressions. Two local progressions and two distant failures occured in stage III patients.

Conclusions

Dose escalation >70 Gy using 3-DCRT in management of NSCLC is feasible with acceptable acute toxicity.

Abstract

Purpose

To determine the feasibility of radiation dose escalation > 70 Gy to Gross Tumour Volume (GTV) using 3-Dimensional Conformal Radiotherapy (3-DCRT).

Methods and Materials

From December 1997 to November 1998, 22 patients with non-small cell lung cancer (NSCLC) were included. Tumour stage was I in 3 cases, II in 6 cases, III in 10 cases, and there were 3 locoregional recurrences after surgery. A 3-D treatment planning system with BEV was used for all patients. Patients underwent limited elective nodal irradiation of 56 Gy. The GTV with 1 cm margin received a dose of at least 70 Gy. Acute and late toxicity were estimated according to the RTOG/EORTC score.

Results

The mean follow-up was 217 (80–360) days. Seventeen patients received 74 Gy, two had 72 Gy, and one had 70 Gy. In one patient with the largest irradiation volume a toxic death due to radiation pneumonitis occured. Except this fatality acute toxicity was acceptable. Seventeen patients were evaluable for response. There were 3 (18%) complete responses, all in patients staged I and II, seven (41%) partial responses, 5 (29%) non-responses and two (12%) local progressions. Two local progressions and two distant failures occured in stage III patients.

Conclusions

Dose escalation >70 Gy using 3-DCRT in management of NSCLC is feasible with acceptable acute toxicity.

Get Citation

Keywords

NSCLC; lung cancer; conformal radiotherapy

About this article
Title

Dose escalation using 3-dimensional conformal radiotherapy in management of non-small cell lung cancer; preliminary results on 22 patients

Journal

Reports of Practical Oncology and Radiotherapy

Issue

Vol 4, No 2 (1999)

Pages

29-37

Published online

1999-01-01

DOI

10.1016/S1507-1367(99)70312-3

Bibliographic record

Rep Pract Oncol Radiother 1999;4(2):29-37.

Keywords

NSCLC
lung cancer
conformal radiotherapy

Authors

L. Kępka
P. Kukołowicz
J. Fijuth

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

By "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk, Poland
tel.:+48 58 320 94 94, fax:+48 58 320 94 60, e-mail: journals@viamedica.pl